Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2020 Jun 26

PMID 32584603

Citations 18

Authors

Angela M Moran

Sanjay Ramakrishnan

Catherine A Borg

Clare M Connolly

Simon Couillard

Christine M Mwasuku

Ian D Pavord

Timothy S C Hinks

Lauri Lehtimki

Affiliations

Soon will be listed here.

Citing Articles

Out of Breath, out of Options: Benralizumab as a Last Hope in ICU-Treated Near-Fatal Eosinophilic Asthma: A Case Series.

Conemans L, Demir E, Bischoff M, Franssen F, Simons S Respirol Case Rep. 2025; 13(3):e70117.

PMID: 40078572 PMC: 11903096. DOI: 10.1002/rcr2.70117.

Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma.

Menzella F, Marchi M, Caminati M, Romagnoli M, Micheletto C, Bonato M J Clin Med. 2025; 14(1.

PMID: 39797273 PMC: 11722057. DOI: 10.3390/jcm14010191.

Vectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy.

Gioulvanidou M, Sarklioglu S, Chen X, Lebedeva I, Inalman Y, Pohl M Hum Gene Ther. 2024; 36(1-2):11-27.

PMID: 39725494 PMC: 11839538. DOI: 10.1089/hum.2024.165.

Choosing the Right Biologic for the Right Patient With Severe Asthma.

Couillard S, Jackson D, Pavord I, Wechsler M Chest. 2024; 167(2):330-342.

PMID: 39245321 PMC: 11867899. DOI: 10.1016/j.chest.2024.08.045.

Pediatric eosinophilic gastritis treated with benralizumab: A case report.

Cheung D, Ebach D, Davis B JPGN Rep. 2024; 5(3):394-397.

PMID: 39149169 PMC: 11322020. DOI: 10.1002/jpr3.12088.

References

Smith D, Minthorn E, Beerahee M . Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011; 50(4):215-27. DOI: 10.2165/11584340-000000000-00000. View

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

Bel E, Wenzel S, Thompson P, Prazma C, Keene O, Yancey S . Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371(13):1189-97. DOI: 10.1056/NEJMoa1403291. View

Wang B, Yan L, Yao Z, Roskos L . Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. CPT Pharmacometrics Syst Pharmacol. 2017; 6(4):249-257. PMC: 5397562. DOI: 10.1002/psp4.12160. View

Pavord I, Korn S, Howarth P, Bleecker E, Buhl R, Keene O . Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380(9842):651-9. DOI: 10.1016/S0140-6736(12)60988-X. View

Lambrecht B, Hammad H . The immunology of asthma. Nat Immunol. 2014; 16(1):45-56. DOI: 10.1038/ni.3049. View

Bleecker E, FitzGerald J, Chanez P, Papi A, Weinstein S, Barker P . Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388(10056):2115-2127. DOI: 10.1016/S0140-6736(16)31324-1. View

Ramakrishnan S, Camp J, Vijayakumar B, Hardinge F, Downs M, Russell R . The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach. Am J Respir Crit Care Med. 2020; 201(11):1441-1443. PMC: 7258629. DOI: 10.1164/rccm.202001-0093LE. View

Kolbeck R, Kozhich A, Koike M, Peng L, Andersson C, Damschroder M . MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010; 125(6):1344-1353.e2. DOI: 10.1016/j.jaci.2010.04.004. View

10.

Leckie M, Ten Brinke A, Khan J, Diamant Z, OConnor B, Walls C . Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2001; 356(9248):2144-8. DOI: 10.1016/s0140-6736(00)03496-6. View